X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/biosight-launches-a-phase-12-clinical-trial-of-aspacytarabine-in-combination-with-venetoclax-for-first-line-aml-induction-therapy-followed-by-aspacytarabine-consolidation-301685067.html
https://www.globenewswire.com/news-release/2022/09/22/2521078/22558/en/BioSig-Launches-PURE-EP-Software-Version-6-with-ACCUVIZ-Module.html
https://www.prnewswire.com/news-releases/biosight-granted-orphan-drug-designation-from-the-fda-for-aspacytarabine-for-the-treatment-of-myelodysplastic-syndromes-301596832.html
https://www.globenewswire.com/news-release/2022/01/06/2362832/0/en/Biosight-Reports-Final-Primary-Endpoint-Data-from-Phase-2b-Study-of-Aspacytarabine-BST-236-for-First-Line-Acute-Myeloid-Leukemia-Therapy.html
https://www.globenewswire.com/news-release/2021/11/12/2333405/0/en/Biosight-Announces-Initiation-of-Phase-2-Clinical-Trial-of-Aspacytarabine-for-MDS-and-AML.html
https://www.globenewswire.com/news-release/2021/11/11/2332600/0/en/Biosight-Encourages-Advaxis-Stockholders-to-Vote-FOR-Proposed-Merger.html
https://www.globenewswire.com/news-release/2021/11/03/2326334/0/en/Leading-Independent-Proxy-Advisory-Firm-ISS-Recommends-Advaxis-Stockholders-Vote-FOR-the-Merger-with-Biosight.html
https://www.globenewswire.com/news-release/2021/09/10/2295143/0/en/Advaxis-Reports-3rd-Quarter-Ended-July-31-2021-Financial-Results-and-Provides-a-Business-Update.html
https://www.globenewswire.com/news-release/2021/08/16/2281034/0/en/Biosight-Announces-Initiation-of-Investigator-Sponsored-Phase-2-Clinical-Trial-of-Aspacytarabine-for-Relapsed-Refractory-AML-and-MDS-with-the-Groupe-Francophone-des-My%C3%A9lodysplasies.html
https://www.globenewswire.com/news-release/2021/07/06/2258015/0/en/Advaxis-and-Biosight-Announce-Entry-into-Definitive-Merger-Agreement.html
Market Place
Share 
